Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease.

We report the implantation of patient-derived midbrain dopaminergic progenitor cells, differentiated in vitro from autologous induced pluripotent stem cells (iPSCs), in a patient with idiopathic Parkinson's disease. The patient-specific progenitor cells were produced under Good Manufacturing Practice conditions and characterized as having the phenotypic properties of substantia nigra pars compacta neurons; testing in a humanized mouse model (involving peripheral-blood mononuclear cells) indicated an absence of immunogenicity to these cells. The cells were implanted into the putamen (left hemisphere followed by right hemisphere, 6 months apart) of a patient with Parkinson's disease, without the need for immunosuppression. Positron-emission tomography with the use of fluorine-18-L-dihydroxyphenylalanine suggested graft survival. Clinical measures of symptoms of Parkinson's disease after surgery stabilized or improved at 18 to 24 months after implantation. (Funded by the National Institutes of Health and others.).

[1]  H. An,et al.  Learning from the past: did experience with previous epidemics help mitigate the impact of COVID-19 among spine surgeons worldwide? , 2020, European Spine Journal.

[2]  O. Lavie,et al.  Hazardous Postoperative Outcomes of Unexpected COVID-19 Infected Patients: A Call for Global Consideration of Sampling all Asymptomatic Patients Before Surgical Treatment , 2020, World Journal of Surgery.

[3]  Martin H. Teicher,et al.  Human Autologous iPSC-Derived Dopaminergic Progenitors Restore Motor Function in Parkinson's Disease Models. , 2019, The Journal of clinical investigation.

[4]  B. Carter,et al.  Columnar Injection for Intracerebral Cell Therapy. , 2019, Operative neurosurgery.

[5]  Kwang-Soo Kim,et al.  Pluripotent stem cell-based therapy for Parkinson’s disease: Current status and future prospects , 2018, Progress in Neurobiology.

[6]  Satoshi Morita,et al.  Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model , 2017, Nature.

[7]  A. Björklund,et al.  Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain , 2016, Proceedings of the National Academy of Sciences.

[8]  O. Lindvall.  Clinical translation of stem cell transplantation in Parkinson's disease , 2016, Journal of internal medicine.

[9]  R. Barker,et al.  Cell-based therapies for Parkinson disease—past insights and future potential , 2015, Nature Reviews Neurology.

[10]  D. Surmeier,et al.  Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD , 2011, Nature.

[11]  Shinya Yamanaka,et al.  Immunogenicity of induced pluripotent stem cells. , 2011, Circulation research.

[12]  Marios Politis,et al.  Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.

[13]  Stanley Fahn,et al.  Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and 18F-FDOPA PET Outcomes , 2010, Journal of Nuclear Medicine.

[14]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[15]  D. Brooks.  Neuroimaging in Parkinson’s disease , 2004, NeuroRX.

[16]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[17]  C. Olanow,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[18]  Ole Isacson,et al.  Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease , 1997, Nature Medicine.

[19]  R. Fitzpatrick,et al.  The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease , 1995, Quality of Life Research.

[20]  A. Björklund,et al.  Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) , 1992, The New England journal of medicine.

[21]  Scott T. Grafton,et al.  Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.

[22]  D. Spencer,et al.  Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. , 1992, The New England journal of medicine.

[23]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[24]  R. Penn,et al.  Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. , 1989, The New England journal of medicine.

[25]  O. Lindvall,et al.  Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen , 1987, Annals of neurology.

[26]  A. Björklund,et al.  Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. , 2014, JAMA neurology.